The Predictive Value of Serum Erythropoietin Levels Measured at Diagnosis in Patients With Myelodysplastic Syndromes
Abstract
Objectives : To study the predictive and prognostic values of serum erythropoietin levels (sEPO) measured at diagnosis in lower‐risk myelodysplastic syndromes. Methods : We analyzed clinical associations and prognosis with sEPO in 672/1610 patients with at least one year of follow‐up data in the prospective EUMDS study. Results : sEPO levels increase with WHO subtypes associated with erythroid hypoplasia and poorer risk IPSS‐R scores. sEPO is an independent predictor of transfusion free survival and levels < 200 IU/L predict response to ESA. sEPO is not an independent predictor of overall survival. Conclusions : sEPO predicts transfusion free survival and response to ESA. Trial Registration : The EUMDS Registry (ClinicalTrials.gov: Identifier NCT00600860).
Related
- Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
- The fraction of CD117/c-KIT-expressing erythroid precursors predicts ESA response in low-risk myelodysplastic syndromes.
- Low-dose deferasirox for lower-risk myelodysplastic syndromes after erythropoiesis-stimulating agents (ESA) failure: results of the phase II LODEFI study
- APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis.
- Predictive autoantibodies before the diagnosis of type I diabetes in adults
BibTeX
@article{culligan2026predictive,
title = {{The Predictive Value of Serum Erythropoietin Levels Measured at Diagnosis in Patients With Myelodysplastic Syndromes}},
author = {Dominic Culligan and Adele Taylor and Alexandra Smith and Catherine Cargo and Howard Oster and Argiris Symeonidis and Reinhard Stauder and Saskia Langemeijer and Luca Malcovati and Pierre Fenaux and Jaroslav Čermák and Eva Hellström-Lindberg and Juliet Mills and Ioannis Kotsianidis and Maud d'Aveni and Corine van Marrewijk and Marlijn Hoeks and Theo de Witte and David Bowen and Moshe Mittelman},
journal = {eJHaem},
year = {2026},
month = jul,
doi = {10.1002/jha2.70366},
url = {https://hal.univ-lorraine.fr/hal-05787689v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - The Predictive Value of Serum Erythropoietin Levels Measured at Diagnosis in Patients With Myelodysplastic Syndromes
AU - Dominic Culligan
AU - Adele Taylor
AU - Alexandra Smith
AU - Catherine Cargo
AU - Howard Oster
AU - Argiris Symeonidis
AU - Reinhard Stauder
AU - Saskia Langemeijer
AU - Luca Malcovati
AU - Pierre Fenaux
AU - Jaroslav Čermák
AU - Eva Hellström-Lindberg
AU - Juliet Mills
AU - Ioannis Kotsianidis
AU - Maud d'Aveni
AU - Corine van Marrewijk
AU - Marlijn Hoeks
AU - Theo de Witte
AU - David Bowen
AU - Moshe Mittelman
PY - 2026
DA - 2026/07/29
JO - eJHaem
DO - 10.1002/jha2.70366
UR - https://hal.univ-lorraine.fr/hal-05787689v1
AB - Objectives : To study the predictive and prognostic values of serum erythropoietin levels (sEPO) measured at diagnosis in lower‐risk myelodysplastic syndromes. Methods : We analyzed clinical associations and prognosis with sEPO in 672/1610 patients with at least one year of follow‐up data in the prospective EUMDS study. Results : sEPO levels increase with WHO subtypes associated with erythroid hypoplasia and poorer risk IPSS‐R scores. sEPO is an independent predictor of transfusion free survival and levels < 200 IU/L predict response to ESA. sEPO is not an independent predictor of overall survival. Conclusions : sEPO predicts transfusion free survival and response to ESA. Trial Registration : The EUMDS Registry (ClinicalTrials.gov: Identifier NCT00600860).
SN - 2688-6146
ER -